Leerink Partners Upgrades Gossamer Bio to Outperform, Maintains Price Target to $1

Benzinga · 1d ago
Leerink Partners analyst Joseph Schwartz upgrades Gossamer Bio (NASDAQ:GOSS) from Market Perform to Outperform and maintains the price target from $1 to $1.